The trademark application CANTEX was filed by Cantex Pharmaceuticals, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on August 14, 2023, and it was registered by office on November 21, 2023 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Change of name and professional address of the trademark registration was recorded on August 6, 2024.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceuticals
Pharmaceutical preparations for the treatment of cancer and other serious illnesses
Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses
Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases
Pharmaceutical preparations for use in personalized medicine and targeted therapy.
The mark was filed in class 42 with following description of goods:
Pharmaceutical research and development
Development of new drugs for the prevention and treatment of cancer and other serious illnesses
Design and testing of new drugs and therapies
Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases
Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases
Biological testing and research in the field of pharmaceuticals
Providing medical and scientific research information about the diagnosis and treatment of diseases
Providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
The mark was filed in class 44 with Providing information in the fields of health and wellness (health), and pharmaceuticals via a website.
The mark was filed in class 45 with Licensing of pharmaceuticals and drug discovery technologies.